Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00805246 · ClinicalTrials.gov registry record

Assessing the Prognosis of Pulmonary Embolism Using Clinical and Imaging Biomarkers (Retrospective & Prospective )

A clinical trial, sponsored by University of Pittsburgh.

Completed
Registry status
910
Enrollment target

NCT00805246: Completed study, sponsored by University of Pittsburgh.

NCT00805246 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 910 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00805246 has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
910 participants
Enrollment target

Study Summary

Venous thromboembolism (VTE), which clinically manifests as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common but elusive illness that can cause significant disability and death if not promptly diagnosed and effectively treated. The annual incidence of VTE in the United States is estimated at 1 per 1000. Death occurs in approximately 12% of PE cases within 1 month of diagnosis. At present, clinical management of VTE and PE is hampered by gaps in our understanding of pathogenic mechanisms, the wide variety in patient populations, and incomplete understanding of the long term risks of recurrence and death. Given the complex presentation and risk associated with these conditions, proper risk assessment and subsequent prophylaxis for all at-risk patients is crucial. While clinical prediction rules have been recently developed to associate short-term risks and to stratify patients with acute PE, there is a dearth of objective biomarkers that can be related to the long-term prognosis of the disease. In addition to clinical information, clot burden is known to be strongly associated with clinical outcome of recurrent VTE. The quantification of clot burden requires imaging. CT Pulmonary Angiography (CTPA) has been established as a reference imaging standard in the diagnosis of PE. In addition to its role as a superb diagnostic tool, CTPA contains a wealth of information including characteristics of the clot that may be used as biomarkers associated with prognosis of PE. The work proposed in this application takes advantage of widely available CTPA imaging biomarker data and extends and advances clinical PE risk prediction model to include long term (2-year) survival as well as the clinically important outcome of recurrence. The primary objective of this proposal is to develop and identify CTPA imaging biomarkers that are associated with short-term and long-term prognoses of patients who were positively diagnosed for PE by CT. The rationale for this propos

Trial Details

FieldValue
Enrollment Target 910 participants
Start Date 2008-12
Est. Completion 2017-05
University of Pittsburgh

1,238 total trials

What the finished NCT00805246 record still lists

NCT00805246 is an observational study that tracks outcomes without assigning an intervention. The registered 910 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00805246 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00805246 about?

NCT00805246 is a clinical study titled "Assessing the Prognosis of Pulmonary Embolism Using Clinical and Imaging Biomarkers (Retrospective & Prospective )". Venous thromboembolism (VTE), which clinically manifests as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common but elusive illness that can cause significant disability and death if not promptly diagnosed and effectively treated. The annual incidence of VTE in the United States is e...

What is the current status of trial NCT00805246?

This trial is currently completed. The enrollment target is 910 participants. The study started on 2008-12. Estimated completion is 2017-05.

Who is sponsoring clinical trial NCT00805246?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06216548 · 909 participants · NA

    E-PRIME For Children With Medical Complexity

  • NCT05658497 · 908 participants

    Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

  • NCT06131840 · 914 participants · Phase 1

    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • NCT05739955 · 918 participants · NA

    Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00805246, the US trial registry maintained by the National Library of Medicine. NCT00805246 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.